<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052013</url>
  </required_header>
  <id_info>
    <org_study_id>CPTK787 0144</org_study_id>
    <nct_id>NCT00052013</nct_id>
  </id_info>
  <brief_title>Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584</brief_title>
  <official_title>A Phase II Open-Label Study of Oral, Continuous, Once Daily PTK787/ZK 222584 in Patients With Von Hippel-Lindau Disease (VHL) and Hemangioblastoma (HB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether PTK787/ZK 222584 is effective in treating
      hemangioblastoma of the brain and/or retina in patients with von Hippel-Lindau disease. The
      study will also assess safety and tolerability of PTK787/ZK 222584, and changes in markers of
      angiogenesis (new blood vessel growth).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate efficacy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate changes in dynamic contrast enhanced magnetic resonance imaging</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the correlation of the pharmacokinetics</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in surrogate markers of angiogenesis</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Von Hippel-Lindau Disease</condition>
  <condition>CNS Hemangioblastoma</condition>
  <condition>Retinal Hemangioblastoma</condition>
  <arm_group>
    <arm_group_label>PTK787/ZK 222584</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTK787/ZK 222584</intervention_name>
    <arm_group_label>PTK787/ZK 222584</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Confirmed diagnosis of VHL disease

          -  One or more measurable CNS hemangioblastoma, if symptomatic, must be refractory or not
             amenable to standard therapy, if asymptomatic, must have had at least one prior
             neurosurgical treatment/ procedure; and/or: at least one untreatable or
             treatment-refractory retinal hemangioblastoma that is causing impaired visual function

          -  Karnofsky Performance Status &gt;=60

          -  Life expectancy &gt; 3 months

          -  Able to sign informed consent

          -  Adequate hematologic status, liver and kidney function

        Exclusion criteria:

          -  Patients with other VHL-related tumors requiring or amenable to standard treatment

          -  Severe or uncontrolled concurrent illnesses that could compromise participation in the
             study

          -  Total urinary protein in 24 hour collection &gt; 500 mg

          -  Pregnant or breast feeding females, adults of reproductive potential not using
             effective contraception (hormonal methods not considered effective due to possible
             decreased effectiveness secondary to drug interaction with PTK787). Women of
             childbearing potential must have negative serum pregnancy test prior to initiation of
             treatment.

          -  Acute or chronic liver disease

          -  Diagnosis of HIV infection

          -  GI function that may alter absorption of PTK787

          -  Patients taking coumadin (warfarin sodium)

          -  Prior therapies (investigational drugs, chemotherapy) within 4 weeks prior to study
             entry

          -  Prior therapies (biologic, hormonal, immunotherapy, radiation therapy, surgery) within
             two weeks prior to study entry.

          -  Patients unwilling or unable to comply with protocol requirements

          -  Patients with concurrent, non VHL-related malignancies other than non-melanoma skin
             cancer

          -  Patients with contraindication to MRI imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=4963</url>
    <description>CPTK787 0144 results on the Novartis Clinical Trials Website</description>
  </link>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2003</study_first_submitted>
  <study_first_submitted_qc>January 21, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2003</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>von Hippel-Lindau disease,</keyword>
  <keyword>CNS,</keyword>
  <keyword>hemangioblastoma,</keyword>
  <keyword>retinal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Hippel-Lindau Disease</mesh_term>
    <mesh_term>Hemangioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vatalanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

